Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid

被引:64
作者
Ikeda, T
Nakata, Y
Kimura, F
Sato, K
Anderson, K
Motoyoshi, K
Sporn, M
Kufe, D
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Dartmouth Coll, Dept Pharmacol, Hanover, NH 03755 USA
关键词
D O I
10.2463/mrms.3.39
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The synthetic oleanane triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and its chemical derivatives induce differentiation and apoptosis of human leukemia cells. The precise mechanisms responsible for the effects of CDDO, however, remain unclear. In the present study, we examined the effects of CDDO and its C-28 imidazolide ester (CDDO-Im) on apoptosis of multiple myeloma (MM) cells. The results show that both CDDO and CDDO-Im are potent inducers of MM cell apoptosis and that CDDO-Inn is more active than CDDO. CDDO-Inn treatment was associated with (a) depletion of glutathione, (b) increases in reactive oxygen species, (c) a reduction of the Fas-associated death domain (FADD)-like interleukin-1-converting enzyme (FLICE) inhibitory protein, (d) activation of caspase-8, and (e) a decrease of the mitochondrial transmembrane potential. The reducing agents, N-acetyl-L-cysteine, DTT, and catalase inhibited each of these CDDO-Im-induced proapoptotic signals. Inhibition of caspase-8 with z-IETD-fmk also abrogated CDDO-im-induced decreases of the mitochondrial transmembrane potential and inhibited apoptosis. These results demonstrate that CDDO-Im disrupts intracellular redox balance and thereby activates the extrinsic caspase-8-dependent apoptotic pathway. We further show that CDDO-Im induces apoptosis of primary MM cells at submicromolar concentrations and that MM cells are more sensitive to this agent than normal bone marrow mononuclear cells. These results suggest that CDDO compounds have potential as new agents for the treatment of MM.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 43 条
  • [1] BELLAMY WT, 1991, CANCER RES, V51, P995
  • [2] Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death
    Boldin, MP
    Goncharov, TM
    Goltsev, YV
    Wallach, D
    [J]. CELL, 1996, 85 (06) : 803 - 815
  • [3] Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
    Catlett-Falcone, R
    Landowski, TH
    Oshiro, MM
    Turkson, J
    Levitzki, A
    Savino, R
    Ciliberto, G
    Moscinski, L
    Fernández-Luna, JL
    Nuñez, G
    Dalton, WS
    Jove, R
    [J]. IMMUNITY, 1999, 10 (01) : 105 - 115
  • [4] Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
    Dai, J
    Weinberg, RS
    Waxman, S
    Jing, YK
    [J]. BLOOD, 1999, 93 (01) : 268 - 277
  • [5] Enhancement of etoposide (VP-16) cytotoxicity by enzymatic and photodynamically induced oxidative stress
    Gantchev, TG
    Hunting, DJ
    [J]. ANTI-CANCER DRUGS, 1997, 8 (02) : 164 - 173
  • [6] Does the redox status of cytochrome C act as a fail-safe mechanism in the regulation of programmed cell death?
    Hancock, JT
    Desikan, R
    Neill, SJ
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2001, 31 (05) : 697 - 703
  • [7] Molecular mechanisms of novel therapeutic approaches for multiple myeloma
    Hideshima, T
    Anderson, KC
    [J]. NATURE REVIEWS CANCER, 2002, 2 (12) : 927 - 937
  • [8] Ikeda T, 2003, CANCER RES, V63, P5551
  • [9] A new cytokine-dependent monoblastic cell line with t(9;11)(p22;q23) differentiates to macrophages with macrophage colony-stimulating factor (M-CSF) and to osteoclast-like cells with M-CSF and interleukin-4
    Ikeda, T
    Sasaki, K
    Ikeda, K
    Yamaoka, G
    Kawanishi, K
    Kawachi, Y
    Uchida, T
    Takahara, J
    Irino, S
    [J]. BLOOD, 1998, 91 (12) : 4543 - 4553
  • [10] The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism
    Ito, Y
    Pandey, P
    Sporn, MB
    Datta, R
    Kharbanda, S
    Kufe, D
    [J]. MOLECULAR PHARMACOLOGY, 2001, 59 (05) : 1094 - 1099